{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:11:18Z","timestamp":1793682678590,"version":"4.5.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.ygyno.2019.02.014","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T21:04:15Z","timestamp":1550783055000},"page":"416-424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers"],"prefix":"10.1016","volume":"153","author":[{"given":"Katia A.","family":"Mesquita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muslim","family":"Alabdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Toss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek M.A. Abdel","family":"Fatah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Alblihy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Moseley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Y.T.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad A.","family":"Rakha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5354-5480","authenticated-orcid":false,"given":"Srinivasan","family":"Madhusudan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.02.014_bb0005","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0010","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0020","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1007\/s00018-016-2218-x","article-title":"Cohn. Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathway","volume":"73","author":"David Lopez-Martinez","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0025","first-page":"1586","article-title":"Aparicio et al. combination platinum-based and DNA damage response-targeting cancer therapy: evolution and future directions","volume":"24","author":"Spyridon","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0030","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1038\/s41467-018-05228-y","article-title":"Lee et al. the therapeutic significance of mutational signatures from DNA repair deficiency in cancer","volume":"9","author":"Jennifer Ma","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0035","article-title":"Sequential recruitment of the repair factors during NER: the role of XPG in initiating the resynthesis step","volume":"27","author":"Vincent Mocquet","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0040","first-page":"1318","article-title":"Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality","volume":"39","author":"George","year":"2017","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/cr.2008.6","article-title":"Transcription-coupled nucleotide excision repair in mammalian cells: molecular mechanisms and biological effects","volume":"18","author":"Mullenders","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0050","doi-asserted-by":"crossref","first-page":"26632","DOI":"10.1074\/jbc.C000337200","article-title":"Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair\/recombination nuclease","volume":"275","author":"WRK","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0055","article-title":"Advances in understanding the complex mechanisms of DNA interstrand cross-link repair","volume":"5","author":"Cheryl Clauson","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0060","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1038\/onc.2013.311","article-title":"A high-throughput screen identifies PARP1\/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer","volume":"32","author":"Postel-Vinay","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2019.02.014_bb0065","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/carcin\/bgs393","article-title":"PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells","volume":"34","author":"Cheng","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ygyno.2019.02.014_bb0070","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/1476-4598-9-248","article-title":"Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression","volume":"9","author":"Usanova","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ygyno.2019.02.014_bb0075","doi-asserted-by":"crossref","first-page":"9990","DOI":"10.1093\/nar\/gks818","article-title":"DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy","volume":"40","author":"McNeil","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0080","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.dnarep.2010.03.010","article-title":"Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells","volume":"9","author":"Arora","year":"2010","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.ygyno.2019.02.014_bb0085","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bbrc.2004.12.008","article-title":"Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin","volume":"327","author":"Chang","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0090","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1755-148X.2011.00882.x","article-title":"Identification of DNA repair gene Ercc1 as a novel target in melanoma","volume":"24","author":"Song L1","year":"2011","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0095","doi-asserted-by":"crossref","first-page":"369","DOI":"10.4155\/bio.12.325","article-title":"Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer","volume":"5","author":"Cimino","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ygyno.2019.02.014_bb0100","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.5858\/arpa.2016-0006-OA","article-title":"Development and validation of an ERCC1 immunohistochemistry assay for solid tumors","volume":"140","author":"Bahamon","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0105","first-page":"12","article-title":"High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer","author":"Du","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0110","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/IGC.0b013e3181a12e09","article-title":"The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer","volume":"19","author":"Steffensen","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2019.02.014_bb0115","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ygyno.2012.01.008","article-title":"Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes","volume":"125","author":"Rubatt","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0120","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40661-017-0055-8","article-title":"PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers","volume":"4","author":"Edessa","year":"2017","journal-title":"Gynecol. Oncol. Res. Pract."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0125","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1517\/14656566.2015.1100168","article-title":"Advances in PARP inhibitors for the treatment of breast cancer","volume":"16","author":"Dizdar","year":"2015","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0130","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.mam.2013.01.006","article-title":"Therapeutic applications of PARP inhibitors: anticancer therapy and beyond","volume":"34","author":"Curtin","year":"2013","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.ygyno.2019.02.014_bb0135","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/1541-7786.MCR-13-0502","article-title":"Base excision repair defects invoke hypersensitivity to PARP inhibition","volume":"12","author":"Horton","year":"2014","journal-title":"Mol. Cancer Res."},{"issue":"24","key":"10.1016\/j.ygyno.2019.02.014_bb0140","doi-asserted-by":"crossref","first-page":"6818","DOI":"10.1158\/0008-5472.CAN-18-0633","article-title":"Targeting PARP1 in XRCC1 deficient sporadic invasive breast cancer or pre-invasive ductal carcinoma in situ induces synthetic lethality and chemoprevention","volume":"78","author":"Ali","year":"2018","journal-title":"Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819301246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819301246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:44:23Z","timestamp":1758771863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819301246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0090825819301246"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.02.014","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}